Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis

October 17, 2016 | On Oct. 10, Exelixis announced results from its phase 2 CABOSUN study of Cabometyx in patients with previously untreated advanced kidney cancer. This clinical trial was structured as a head-to-head comparison between Cabometyx and Pfizer's Sutent, and Cabometyx emerged as the clear winner. The Motley Fool